Urgent Surgery Clinical Trial
Official title:
A Randomized Study of Andexanet Alfa Compared to Usual Care in Patients Receiving a Factor Xa Inhibitor Who Require Urgent Surgery or Procedure (ANNEXA-RS)
The study will aim to find out if the drug andexanet alfa is safe and effective in preventing major bleeding during urgent surgery or invasive procedures. The study will compare the use of andexanet alfa to the usual care given at the study center.
This study will be an open-label, randomised, controlled, prospective, multicenter study. The study will include patients requiring urgent surgery or procedure that needs to be performed within 15 hours of the last dose of blood-thinning drug (direct oral activated Factor X (FXa) inhibitor). The study will comprise of the following periods: - Screening, followed by surgery or procedure and study intervention. - Follow-up period: there will be four follow-up visits over a duration of approximately 30 days. - Follow-up visit for patients with positive anti-andexanet alfa antibody test: patients with a positive anti-andexanet alfa antibody response at day 30 will have a follow-up anti-andexanet alfa antibody test approximately 120 days post-surgery or procedure. Patients will be randomised in the ratio of 1:1 to receive either andexanet alfa or usual care. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04286438 -
Bentracimab in Ticagrelor-treated Patients With Uncontrolled Bleeding or Requiring Urgent Surgery or Invasive Procedure
|
Phase 3 | |
| Withdrawn |
NCT03537521 -
Reversal Agent Use in Patients Treated With Direct Oral Anticoagulants or Vitamin K Antagonists (RADOA). Focus on New Antidots
|
||
| Completed |
NCT01722786 -
Reversal Agent Use in Patients Treated With Direct Oral Anticoagulants or Vitamin K Antagonists
|